(Q54582432)

1 June 2018

title

Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. (English)

1 reference

1 June 2018

1 reference

8

1 reference

1 June 2018

Anita Langerød

6

object named as

Anita Langerød

1 reference

1 June 2018

2

Annegien Broeks

1 reference

1 June 2018

author name string

Alexandra J van den Broek

1

1 reference

1 June 2018

Hugo M Horlings

3

1 reference

1 June 2018

Sander V M Canisius

4

1 reference

1 June 2018

Linde M Braaf

5

1 reference

1 June 2018

Laura J Van't Veer

7

1 reference

1 June 2018

language of work or name

English

0 references

publication date

11 June 2011

1 reference

1 June 2018

Breast Cancer Research and Treatment

published in

1 reference

1 June 2018

volume

130

1 reference

1 June 2018

issue

2

1 reference

1 June 2018

page(s)

599-608

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1007/s10549-011-1615-y

exact match

0 references

cites work

The DNA damage response: putting checkpoints in perspective

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

MDM2 is a central node in the p53 pathway: 12 years and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

The p53-Mdm2 module and the ubiquitin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

p53 polymorphisms: cancer implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Primary structure polymorphism at amino acid residue 72 of human p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

The polyproline region of p53 is required to activate apoptosis but not growth arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Identification of a novel p53 functional domain that is necessary for efficient growth suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

The codon 72 polymorphic variants of p53 have markedly different apoptotic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

p53 polymorphic variants at codon 72 exert different effects on cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Two polymorphic variants of wild-type p53 differ biochemically and biologically

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Why is PTEN an important tumor suppressor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

21 January 2018

TP53 and breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

Translating p53 into the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

LOH rather than genotypes ofTP53codon 72 is associated with disease-free survival in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1615-Y

10.1007/S10549-011-1615-Y

21 January 2018

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018